scholarly journals Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to 7 criteria – multicenter analysis

2021 ◽  
Author(s):  
Atsushi Hiraoka ◽  
Takashi Kumada ◽  
Toshifumi Tada ◽  
Masashi Hirooka ◽  
Kazuya Kariyama ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Early Experience ◽  
Unresectable Hepatocellular Carcinoma ◽  
Bevacizumab Treatment ◽  
Multicenter Analysis

PS-136-Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis

2019 ◽  
Vol 70 (1) ◽  
pp. e87-e88
Author(s):  
Atsushi Hiraoka ◽  
Takashi Kumada ◽  
Koichi Takaguchi ◽  
Kazuya Kariyama ◽  
tsuji kunihiko ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Unresectable Hepatocellular Carcinoma ◽  
Multicenter Analysis

scholarly journals Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis

2018 ◽  
Vol 8 (1) ◽  
pp. 137-146 ◽  
Author(s):  
Atsushi Hiraoka ◽  
Takashi Kumada ◽  
Kazuya Kariyama ◽  
Koichi Takaguchi ◽  
Masanori Atsukawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Features ◽  
Real World ◽  
Unresectable Hepatocellular Carcinoma ◽  
Multicenter Analysis

scholarly journals Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

2019 ◽  
Vol 8 (8) ◽  
pp. 3719-3728 ◽  
Author(s):  
Atsushi Hiraoka ◽  
Takashi Kumada ◽  
Masanori Atsukawa ◽  
Masashi Hirooka ◽  
Kunihiko Tsuji ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Prognostic Factor ◽  
Real World ◽  
Unresectable Hepatocellular Carcinoma ◽  
Multicenter Analysis
Sign in / Sign up

Export Citation Format

Share Document